AffyXell snags $7.3m Series A
AffyXell Therapeutics, a developer of novel mesenchymal stem cell therapies, has raised $7.3 million in Series A funding.
AffyXell Therapeutics, a developer of novel mesenchymal stem cell therapies, has raised $7.3 million in Series A funding.
Copyright PEI Media
Not for publication, email or dissemination